Matches in SemOpenAlex for { <https://semopenalex.org/work/W2519291224> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2519291224 endingPage "83" @default.
- W2519291224 startingPage "979" @default.
- W2519291224 abstract "Taste alteration is an adverse effect of cancer chemotherapy that can cause a decrease in the nutritional status owing to appetite suppression. In most cases, taste alteration is attributed to zinc deficiency, which is treated using zinc-containing formulations, such as polaprezinc. Polaprezinc has commonly been administered to protect against taste alteration during the course of cancer chemotherapy, but its efficacy has not been fully evaluated. In addition, the background characteristics of the patients who are likely to experience taste alteration have not been fully investigated. Therefore, the effectiveness of zinccontaining formulations in the prevention of taste alteration was investigated retrospectively in our hospital. The objective of this study was to evaluate the presence of taste alteration and the effectiveness of polaprezinc administration in 136 female breast cancer patients who underwent FEC100 therapy between April 2011 and September 2014. We also investigated the relevance of the patient background factors in the occurrence of taste alteration(age, height, weight, body surface area, and levels of hemoglobin, serum iron, albumin, and total protein). Of 58 patients with taste alteration, 20 received polaprezinc, with the following outcomes: taste alteration improved in 70.0% of the patients, no change was observed in 25.0%, and the condition worsened in 5.0%. In a multiple regression analysis, the body surface area and decreased hemoglobin level were found to be significant independent factors that influence the development of taste alteration(p=0.003 and p=0.021, respectively). These results indicate that for patients who receive high doses of anticancer agents according to their body surface area and likelihood of anemia, such as that due to iron deficiency, early administration of zinc-containing formulations is anticipated to prevent taste alteration." @default.
- W2519291224 created "2016-09-23" @default.
- W2519291224 creator A5004366135 @default.
- W2519291224 creator A5006302251 @default.
- W2519291224 creator A5019325551 @default.
- W2519291224 creator A5031170708 @default.
- W2519291224 creator A5035100784 @default.
- W2519291224 creator A5035470630 @default.
- W2519291224 creator A5089610702 @default.
- W2519291224 date "2016-08-01" @default.
- W2519291224 modified "2023-09-23" @default.
- W2519291224 title "[The Effectiveness of Polaprezinc Preparation for Taste Alteration in Cancer Chemotherapy]." @default.
- W2519291224 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27539040" @default.
- W2519291224 hasPublicationYear "2016" @default.
- W2519291224 type Work @default.
- W2519291224 sameAs 2519291224 @default.
- W2519291224 citedByCount "2" @default.
- W2519291224 countsByYear W25192912242017 @default.
- W2519291224 countsByYear W25192912242022 @default.
- W2519291224 crossrefType "journal-article" @default.
- W2519291224 hasAuthorship W2519291224A5004366135 @default.
- W2519291224 hasAuthorship W2519291224A5006302251 @default.
- W2519291224 hasAuthorship W2519291224A5019325551 @default.
- W2519291224 hasAuthorship W2519291224A5031170708 @default.
- W2519291224 hasAuthorship W2519291224A5035100784 @default.
- W2519291224 hasAuthorship W2519291224A5035470630 @default.
- W2519291224 hasAuthorship W2519291224A5089610702 @default.
- W2519291224 hasConcept C121608353 @default.
- W2519291224 hasConcept C126322002 @default.
- W2519291224 hasConcept C185592680 @default.
- W2519291224 hasConcept C197934379 @default.
- W2519291224 hasConcept C2776694085 @default.
- W2519291224 hasConcept C2777501473 @default.
- W2519291224 hasConcept C2908742984 @default.
- W2519291224 hasConcept C31903555 @default.
- W2519291224 hasConcept C71924100 @default.
- W2519291224 hasConcept C8868529 @default.
- W2519291224 hasConcept C90924648 @default.
- W2519291224 hasConceptScore W2519291224C121608353 @default.
- W2519291224 hasConceptScore W2519291224C126322002 @default.
- W2519291224 hasConceptScore W2519291224C185592680 @default.
- W2519291224 hasConceptScore W2519291224C197934379 @default.
- W2519291224 hasConceptScore W2519291224C2776694085 @default.
- W2519291224 hasConceptScore W2519291224C2777501473 @default.
- W2519291224 hasConceptScore W2519291224C2908742984 @default.
- W2519291224 hasConceptScore W2519291224C31903555 @default.
- W2519291224 hasConceptScore W2519291224C71924100 @default.
- W2519291224 hasConceptScore W2519291224C8868529 @default.
- W2519291224 hasConceptScore W2519291224C90924648 @default.
- W2519291224 hasIssue "8" @default.
- W2519291224 hasLocation W25192912241 @default.
- W2519291224 hasOpenAccess W2519291224 @default.
- W2519291224 hasPrimaryLocation W25192912241 @default.
- W2519291224 hasRelatedWork W1994345703 @default.
- W2519291224 hasRelatedWork W2071568098 @default.
- W2519291224 hasRelatedWork W2325714878 @default.
- W2519291224 hasRelatedWork W2371666691 @default.
- W2519291224 hasRelatedWork W2378355431 @default.
- W2519291224 hasRelatedWork W2417906828 @default.
- W2519291224 hasRelatedWork W2418617970 @default.
- W2519291224 hasRelatedWork W2472246853 @default.
- W2519291224 hasRelatedWork W2794260504 @default.
- W2519291224 hasRelatedWork W3159307090 @default.
- W2519291224 hasVolume "43" @default.
- W2519291224 isParatext "false" @default.
- W2519291224 isRetracted "false" @default.
- W2519291224 magId "2519291224" @default.
- W2519291224 workType "article" @default.